Oral prednisolone,
does it really help with Reducing cough duration and symptom severity in adults without asthma who have acute lower respiratory tract infection?
research showsOral prednisolone is rated D for cough from acute lower respiratory tract infection in adults without asthma. OSAC randomized 401 people and excluded three ineligible participants, leaving 398 in the baseline analysis. The cough-duration coprimary endpoint failed at five days versus five days, HR 1.11 (95% CI 0.89 to 1.39), and the symptom-severity coprimary endpoint also failed, difference -0.20 (95% CI -0.40 to 0.00). verdict 1183, which is A with 82 points, and verdict 1335, which is C with 46 points, concern different indications.
ads claimThe general anti-inflammatory action is extended into a claim that infection-related cough in adults without asthma will end sooner, but the direct large trial found no benefit for duration or severity.
Useful facts when choosing a product
- The trial regimen was prednisolone 40 mg once daily for five days.
- Asthma or COPD exacerbation, pneumonia, and severe infection requiring immediate antibiotics fall outside this verdict.
- Even short courses can cause insomnia, mood changes, hyperglycemia, and gastrointestinal upset; repeated courses increase risk.
What the research actually shows
Hay and colleagues randomized 401 adults with acute cough and lower respiratory symptoms but no asthma or COPD to prednisolone 40 mg daily for five days or placebo; excluding three ineligible participants left 398 in the baseline analysis. The cough-duration coprimary endpoint failed at five days versus five days, HR 1.11 (95% CI 0.89 to 1.39), and the symptom-severity coprimary endpoint also failed, difference -0.20 (95% CI -0.40 to 0.00). The study had public UK NIHR funding.
Why this is classified as D (25)
Among 401 randomized participants, the actual coprimary analyses included 334 and 369, and both endpoints failed. This is direct null evidence, so the grade is D; without repeated independent failures in the same indication, it is D with 25 points rather than F.
Counterpoint. Persistent cough, dyspnea, high fever, chest pain, or hypoxemia warrants evaluation for pneumonia, asthma, or another cause.
Rejudgment record. Cross-check applied — Among 401 randomized participants and 398 in the baseline analysis, both coprimary endpoints, cough duration and symptom severity, failed separately
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Shorter duration of moderately bad or worse cough | D | The 334-person analysis failed, with a median of five days in both groups. |
| Lower overall symptom severity on days 2 to 4 | D | The 369-person analysis missed the prespecified alpha and clinically important difference. |
| Shorter duration of other acute lower respiratory symptoms | D | Secondary symptom durations also showed no significant effects. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Hay AD et al. 2017 | Multicenter randomized double-blind placebo-controlled trial | 398 | Public funding from the UK NIHR School for Primary Care Research; University of Bristol sponsor, with no manufacturer role | Coprimary endpoints of moderately bad or worse cough duration and symptom severity on days 2 to 4 | Cough duration failed at five days versus five days, HR 1.11 (95% CI 0.89 to 1.39); symptom severity also failed, difference -0.20 (95% CI -0.40 to 0.00). | Key large direct evidence |
| El-Gohary M et al. 2013 | Systematic review of acute and subacute postinfectious cough | 0 | No manufacturer leadership reported; review funding was not clearly stated in the article | Cough scores and duration | Inhaled trials were mixed and the review identified a direct evidence gap for oral prednisolone. | Pre-OSAC evidence context |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Oral prednisolone x cough in nonasthmatic acute lower respiratory tract infection — Evidence Grade D·25. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/oral-prednisolone-acute-lower-respiratory-infection-cough/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.